StemCell Therapy

The European Commission president has said she hopes a vaccine for coronavirus could be ready before the autumn as the bloc puts aside bureaucratic obstacles and races with the US and other geopolitical rivals to tackle the crisis.

Ursula von der Leyen, a former medical doctor, has said a vaccine against the novel coronavirus, known as Covid-19, could be prepared much faster in the face of the global pandemic.

Health authorities have said, however, that it would take another 18 months before the preventative medicine could be put on the market.

The EU has offered CureVac, a biopharmaceutical company headquartered in Tubingen, Germany, 80 million euros to develop a new vaccine to create immunity against Covid-19. The company has said it could begin trails with humans as early as June.

I hope that with this support, we can have a vaccine on the market, perhaps before autumn, Ms Von der Leyen said.

"As we are in a severe crisis, we all see that we are able to speed up any of the processes that are slow normally and take a lot of time and are very bureaucratic," Ms Von der Leyen told reporters later on Tuesday.

Representatives for CureVac have said a vaccine could be ready in time if the German regulator allowed it to fast-track its product. Developing a shot before the autumn would allow nations the opportunity to stop a second seasonal wave of the virus in its tracks.

However, national heath advisors across Europe and the United States have regularly warned a vaccine could not be prepared before the end of 2020.

Curevac has found itself at the centre of a spat between Europe and the United States after reports emerged in the German press that a US official had offered to pay for the rights to the Covid-19 vaccine.

A White House official was reported to have offered large sums of cash for the vaccine on the provision that it was only for the USA.

The biotech company has subsequently had to deny reports that the administration of US President Donald Trump had tried to get hold of the vaccine.

"There was and there is no takeover offer from the White House or governmental authorities. Neither to the technology nor to CureVac at all as a company," CureVac acting CEO Franz-Werner Haas said on Tuesday.

However it has emerged that the US airforce flew 500,000 COVID-19 testing kits from Italy on a C-17 transporter to Tennessee on Monday as Washington uses its resources to fight the spread of the virus within its borders.

At the same time, specialist doctors and medical equipment have arrived in Italy ready to help tackle the sharp spike in people with the disease, which has overwhelmed medical facilities.

The doctors bring with them first-hand experience of dealing with the coronavirus, having previously helped to tackle the original outbreak in China's Hubei province that killed more than 3,000 people. Tough quarantine measures have seen the rate of new cases in China dwindle, while in Europe the outbreak continues to spread.

Updated: March 19, 2020 01:39 AM

Read more from the original source:
Coronavirus: EU head hopes for Covid-19 vaccine by autumn - The National

President Donald Trump said Thursday his administration willmake the malaria drug chloroquine available almost immediately to treat the COVID-19 infection, but it will only be available under the compassionate use program until the drug undergoes a clinical trial under the FDAs directive.

Studies are showing chloroquine can both prevent and treat coronavirus in the cells of primates, but it is not FDA-approved for COVID-19.

Some doctors report very encouragingresults quickly in very sick people, Dr. Jane Orient, executive director of the Association of American Physicians and Surgeons, told Breitbart News about research into chloroquine to treat the COVID-19 also known as SARS-CoV-2 respiratory illness.

Independent doctorsmay prescribe it off-label, but employed physicians might not be allowed to, by corporate administrators, because it is not FDA-approved for this indication, she added. No preventive or therapeutic meds are specifically approved for this.

As Breitbart Newss James Delingpole observed, a study document prepared by Dr. James Todaro and Attorney Gregory Rigano, in association with Stanford University School of Medicine and National Academy of Sciences Researchers, concluded:

Chloroquine can both prevent and treat malaria. Chloroquine can both prevent and treat coronavirus in primate cells (Figure 1 and Figure 2). According to South Korean and China human treatment guidelines, chloroquine is effective in treating COVID-19. Given chloroquines human safety profile and existence, it can be implemented today in the U.S., Europe and the rest of the world. Medical doctors may be reluctant to prescribe chloroquine to treat COVID-19 since it is not FDA approved for this use. The United States of America and other countries should immediately authorize and indemnify medical doctors for prescribing chloroquine to treat COVID-19. We must explore whether chloroquine can safely serve as a preventative measure prior to infection of COVID-19 to stop further spread of this highly contagious virus.

The Centers for Disease Control and Prevention (CDC) states:

Chloroquine is an antimalarial medicine available in the United States by prescription only Chloroquine can be prescribed for eitherprevention or treatmentof malaria. Chloroquine can be prescribed to adults and children of all ages. It can also be safely taken by pregnant women and nursing mothers.

Dr. Martin J. Vincent, et al, also wrote in 2005 in a study published at the National Institutes of Health (NIH) when severe acute respiratory syndrome (SARS) was found to have been caused by coronavirus SARS-CoV:

Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.

We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.

The researchers concluded that chloroquine is effective in preventing the spread of SARS CoV in cell culture.

Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection, they added.

The nice part is its been around for a long time, so we know that if things dont go as planned, its not going to kill anybody, Trump said at a press briefing.

Nevertheless, Dr. Stephen M. Hahn, commissioner of food and drugs at the Food andDrug Administration (FDA), wrote at USA Today Tuesday:

While the Food and Drug Administration is working full speed, in collaboration with public and private sector partners, to help diagnose, treat and prevent this disease, presently there are no FDA-approved products to prevent, treat or cure COVID-19.

Orient said:

We need to get the FDA out of the practice of medicine. Also, it can shut down U.S. productionlines for exceeding production quotas or aminor paperwork violation, but has no meaningful inspection ofplants in China, on which we are dependent for 90% of our drug supply, including antibiotics and other things needed to care for critically ill patients.

Hopefully the Trump administration is working on bringing essential manufacturing home, she concluded.

Meanwhile, Orient recommends that those with a fever only treat it after consultation with a doctor:

Fever is not a disease. It is an important defense mechanism. Very high fevers (say 105 degrees) can cause brain damage, and children can have seizures. But dont pop Tylenol or ibuprofen at the first sign of fever. Many of the casualties in the 1918 pandemic might have been caused by heavy use of aspirin. Like aspirin, popular nonsteroidal anti-inflammatories (NSAIDS), such as ibuprofen, also have detrimental effects on blood clotting. Try lukewarm sponge baths for comfort.

Orient recommends that Americans only go to an emergency room or urgent care facility if they are severely ill. She explained:

There will be sick people there, and you might catch something. You also might end up with a big bill, say for a CT scan you didnt really need. And if you have the flu or a cold or COVID-19, and dont need IV fluids or oxygen, they cant do anything for you.

At home, Orient advises families to clean and disinfect surfaces such as doorknobs, telephones, computer keyboards, toilets, and countertops often.

Virus can persist there for days, she says.

She also urges Americans to ensure they are getting the vitamins they need.

Most people may be vitamin D deficient, she explains. Your need for vitamin C escalates with infection. Some 50 tons of vitamin C was shipped to Wuhan, and studies of effectiveness are underway.

See the rest here:
FDA Urged to Approve Chloroquine to Treat COVID-19 - Breitbart

Update: Wednesday, March 18, 2020New controlled clinical study conducted by doctors in France shows that Hydroxychloroquine cures 100% of coronavirus patients within 6 days of treatment (covidtrial.io)

The coronavirus pandemic has so far claimed7,171 lives, with at least 182,603coronavirus cases reported and79,881 people recovered. Today, the NIH begins clinical trial of investigational vaccine for COVID-19. While the trial launched in record speed, public health officials have been stressing for weeks that a vaccine wont be ready for 12 to 18 months in the best circumstances.

However, there is good news today that an existing anti-viral medication may be effective at treating the COVID-19. According to anew academic studypresented by Thomas R. Broker, (Stanford PhD), James M. Todaro (Columbia MD), and Gregory J. Rigano, Esq., in consultation with Stanford University School of Medicine, UAB School of Medicine, and National Academy of Sciences researchers, shows that over the counter anti-malaria pills Chloroquine may be highly effective at treating coronavirus COVID-19.

In a research work published on Friday, recent guidelines from South Korea and China report that chloroquine is an effective antiviral therapeutic treatment against Coronavirus Disease 2019. Use of chloroquine (tablets) is showing favorable outcomes in humans infected with Coronavirus including faster time to recovery and shorter hospital stay. US CDC research shows that chloroquine also has strong potential as a prophylactic (preventative) measure against coronavirus in the lab, while we wait for a vaccine to be developed. Chloroquine is an inexpensive, globally available drug that has been in widespread human use since 1945 against malaria, autoimmune and various other conditions, the authors said.

According to research by the US CDC, chloroquine has strong antiviral effects on SARS coronavirus, both prophylactically and therapeutically. SARS coronavirus has significant similarities to COVID-19. Specifically, the CDC research was completed in primate cells using chloroquines well known function of elevating endosomal pH. The results show that We have identified chloroquine as an effective antiviral agent for SARS-CoV in cell culture conditions, as evidenced by its inhibitory effect when the drug was added prior to infection or after the initiation and establishment of infection. The fact that chloroquine exerts an antiviral effect during pre- and post-infection conditions suggest that it is likely to have both prophylactic and therapeutic advantages.

Background

The U.S. CDC and World Health Organization have not published treatment measures against Coronavirus disease 2019 (COVID-19). Medical centers are starting to have issues with traditional protocols. Treatments, and ideally a preventative measure, are needed. South Korea and China have had significantly more exposure and time to analyze diagnostic, treatment and preventative options. The U.S., Europe and the rest of the world can learn from their experience. According to former FDA commissioner, board member of Pfizer and Illumina, Scott Gotlieb MD, the world can learn the most about COVID-19 by paying closest attention to the response of countries that have had significant exposure to COVID-19 before the U.S. and Europe.[1]

As per the U.S. CDC, Chloroquine (also known as chloroquine phosphate) is an antimalarial medicine Chloroquine is available in the United States by prescription only Chloroquine can be prescribed for either prevention or treatment of malaria. Chloroquine can be prescribed to adults and children of all ages. It can also be safely taken by pregnant women and nursing mothers.[2]

CDC research also shows that chloroquine can affect virus infection in many ways, and the antiviral effect depends in part on the extent to which the virus utilizes endosomes for entry. Chloroquine has been widely used to treat human diseases, such as malaria, amoebiosis, HIV, and autoimmune diseases, without significant detrimental side effects.[3]

The treatment guidelines of both South Korea and China against COVID-19 are generally consistent, outlining chloroquine as an effective treatment.

Specifically, according to the Korea Biomedical Review, in February 2020 in South Korea, the COVID-19 Central Clinical Task Force, composed of physicians and experts treating patients agreed upon treatment principles for patients with COVID-19.[4] In China, the General Office of the National Health Commission, General Office of the State Administration of Traditional Chinese Medicine as well as a Multi-Center Collaborative Group of Guangdong Provincial Department of Science and Technology and Guangdong Provincial Health Comp and the China National Center for Biotechnology Development have established effective treatment measures based on human studies.[5]

Data from the drugs [chloroquine] studies showed certain curative effect with fairly good efficacy patients treated with chloroquine demonstrated a better drop in fever, improvement of lung CT images, and required a shorter time to recover compared to parallel groups. The percentage of patients with negative viral nucleic acid tests was also higher with the anti-malarial drug Chloroquine has so far shown no obvious serious adverse reactions in more than 100 participants in the trials Chloroquine was selected after several screening rounds of thousands of existing drugs. Chloroquine is undergoing further trials in more than ten hospitals in Beijing, Guangdong province and Hunnan province.[6]

According to the Korea Biomedical Review, the South Korean COVID-19 Central Clinical Task Force guidelines are as follows:

1. If patients are young, healthy, and have mild symptoms without underlying conditions, doctors can observe them without antiviral treatment;

2. If more than 10 days have passed since the onset of the illness and the symptoms are mild, physicians do not have to start an antiviral medication;

3. However, if patients are old or have underlying conditions with serious symptoms, physicians should consider an antiviral treatment. If they decide to use the antiviral therapy, they should start the administration as soon as possible:

chloroquine 500mg orally per day.

4. As chloroquine is not available in Korea, doctors could consider hydroxychloroquine 400mg orally per day (Hydroxychloroquine is an analog of chloroquine used against malaria, autoimmune disorders, etc. It is widely available as well).

5. The treatment is suitable for 7 10 days, which can be shortened or extended depending on clinical progress.

Notably, the guidelines mention other antivirals as further lines of defense, including anti-HIV drugs.

According to Chinas Novel Coronavirus Pneumonia Diagnosis and Treatment Plan, 7th Edition, the treatment guidelines are as follows:

1. Treatment for mild cases includes bed rest, supportive treatments, and maintenance of caloric intake. Pay attention to fluid and electrolyte balance and maintain homeostasis. Closely monitor the patients vitals and oxygen saturation.

2. As indicated by clinical presentations, monitor the hematology panel, routine urinalysis, CRP, biochemistry (liver enzymes, cardiac enzymes, kidney function), coagulation, arterial blood gas analysis, chest radiography, and so on. Cytokines can be tested, if possible.

3. Administer effective oxygenation measures promptly, including nasal catheter, oxygen mask, and high flow nasal cannula. If conditions allow, a hydrogen-oxygen gas mix (H2/O2: 66.6%/33.3%) may be used for breathing.

4. Antiviral therapies:

chloroquine phosphate (adult 18-65 years old weighing more than 50kg: 500mg twice daily for 7 days; bodyweight less than 50kg: 500mg twice daily for day 1 and 2, 500mg once daily for day 3 through 7)

Additionally, the Guangdong Provincial Department of Science and Technology and the Guangdong Provincial Health and Health Commission issued a report stating Expert consensus on chloroquine phosphate for new coronavirus pneumonia: clinical research results show that chloroquine improves the success rate of treatment and shortens the length of patients hospital stay.[9] The report further goes on to cite research from the US CDC from 2005 as well as research from the University of Leuven University in Belgium regarding chloroquines effectiveness against SARS coronavirus at the cellular level.[10]

Like the South Korean guidelines, notably, other antivirals (e.g. anti-HIV drugs) are listed as further lines of defense. The most research thus far has been around chloroquine.

Chloroquine as a prophylactic (preventative) measure against COVID-19[11]

According to research by the US CDC, chloroquine has strong antiviral effects on SARS coronavirus, both prophylactically and therapeutically. SARS coronavirus has significant similarities to COVID-19. Specifically, the CDC research was completed in primate cells using chloroquines well known function of elevating endosomal pH. The results show that We have identified chloroquine as an effective antiviral agent for SARS-CoV in cell culture conditions, as evidenced by its inhibitory effect when the drug was added prior to infection or after the initiation and establishment of infection. The fact that chloroquine exerts an antiviral effect during pre- and post-infection conditions suggest that it is likely to have both prophylactic and therapeutic advantages.

In conclusion, the study shows that chloroquine is effective in preventing SARS-CoV infection in cell culture if the drug is added to the cells 24 h prior to infection.

You can read the rest of the report here.

Read more from the original source:
New academic study reveals over-the-counter anti-malaria med Chloroquine may be highly effective at treating coronavirus - TechStartups.com

By AGGREY MUTAMBOMore by this Author

Authorities in South Korea have rued the missed chance they had in arresting the surge of coronavirus cases in their country, when they let a suspected patient walk back to her community.

By Tuesday this week, South Koreas Centres for Disease Control had reported 8,320 cases of Covid-19, 81 deaths and 1,401 fully recovered patients.

Though Seoul reported its first case of Covid-19 on January 20, officials say it shouldnt have spread this way.

It all began on February 18, when a woman only identified as Patient 31 checked into a South Korean hospital displaying symptoms associated with the new coronavirus. But the woman reportedly refused to take a Covid-19 test even after her doctor advised it.

It turned out she was a member of the Shincheonji, Church of Jesus, the Temple of the Tabernacle of the Testimony (SCJ), a highly secretive sect in South Korea and which the Korean CDC says two thirds of the Covid-19 cases in the country are associated with.The woman, 61, came from Daegu, a city in South Korea with about 2.5 million people, where the church has a significant following.

South Korean officials say the woman initially refused to take the test as she feared it could lead to her revealing her church members. She also insisted that she had not travelled overseas and had not contacted an infected person. The woman would later be forced back to the hospital after her condition became worse. But she had infected many more of her church members.The Church, began in 1984 by leader Lee Man-hee, who is seen as the only interpreter of the Book of Revelations, follows some secretive practices including keeping their membership to themselves. The Korean CDC, however, found the church had a branch in Wuhan in China, where the virus was first reported, and some members had travelled from there recently.

Inside South Korea, their members prayed close to each other, operated in secrecy, and accessed the church using a finger-print reading system. And as each member placed a finger on the same surface, it is possible the virus spread among members, before spreading to nearby communities. All this time, Korean authorities were legally barred from interfering with freedom of worship. Three days after Patient 31 showed up in hospital, South Koreas cases reached 346, becoming the biggest incidences reported outside China then.Korean officials last week reported more recoveries than infections. The country largely depended on lessons learnt from the missed opportunity, according to a report by the local CDC.The Churchs officials put out a statement denying they hindered preventive measures.

Controlling and preventing infectious diseases is a serious matter which is directly related to the health of people and may cause social anxiety from concerns of infection. The church is assisting in thorough investigation and diagnosis following the instructions of the health department, the Church says on a statement on its website.Whether their practices hindered prevention or not, reflects how deep religious beliefs and misinformation about medical facts may hinder combating the virus.

In east Africa, where coronavirus cases have risen, experts warned misinformation or dangerous beliefs could be just as harmful.

In Kenya, for example, authorities have in the past used force to implement some medical programmes like polio immunisation, especially in communities that follow stringent religious beliefs against medication. Others choose to believe their deities rather than advice from medical experts.

It appears to be in our nature to consistently appeal to supernatural forces whenever faced with a serious threat instead of taking practical measures to deal with emergent threats, Sunday Nation columnist Lukoye Atwoli, an associate professor of psychiatry at Moi University School of Medicine, said in his column.When it comes to public health, it is important to understand the science behind a problem in order to be able to control it.

In Korea, authorities began a programme where motorists can drive through a centre, give samples and be contacted later in case they test positive. That has helped reduce the rates of infections.

An analysis by the Poynter Institute last week found a series of misinformation concerning religion and races, where false purveyors claimed some religions can be good shields against Covid-19.

Religion is not a way to protect yourself against the new disease, the Institute observed.

These beliefs can keep infected people away from real treatment, and those who are at risk of contamination far from preventative measures, promoting real harm.Last year, the World Health Organisation had to appeal to Facebook to flag false information about vaccines, after the global health body was met with rising advocates against immunisation.

WHO Director-General Dr Tedros Adhanom Ghebreyesus said, Vaccine misinformation is a major threat to global health that could reverse decades of progress made in tackling preventable diseases.

Many debilitating and deadly diseases can be effectively prevented by vaccines. Think measles, diphtheria, hepatitis, polio, cholera, yellow fever, influenzaCovid-19 doesnt have a vaccine yet, but Dr Tedros admitted recently that misinformation about the virus was still a challenge.

In East Africa though, officials have also been pushed to advise against cash to prevent potential spread of the coronavirus pandemic.

Someone like a tout who collects cash all the time should put on disposable gloves, said Dr Diana Atwine, Ugandas Permanent Secretary in the Ministry of Health, in a series of public awareness tweets on Monday.

Money has been proven to be a great source of infections, she said.

In Nairobi, President Uhuru Kenyatta called on vendors to facilitated use of non-cash payments. But all the East African countries use public transport systems where service providers largely accept cash payments.

See the rest here:
Lessons from South Korea on Covid-19 preventive measures - The East African

A public service announcement about coronavirus prevention is displayed on an electronic traffic message board as an ambulance travels northbound on Chicagos Dan Ryan Expressway, Thursday, March 19, 2020. (AP Photo/Charles Rex Arbogast)

A public service announcement about coronavirus prevention is displayed on an electronic traffic message board as an ambulance travels northbound on Chicagos Dan Ryan Expressway, Thursday, March 19, 2020.

A public service announcement about coronavirus prevention is displayed on an electronic traffic message board as an ambulance travels northbound on Chicagos Dan Ryan Expressway, Thursday, March 19, 2020. (AP Photo/Charles Rex Arbogast)

A public service announcement about coronavirus prevention is displayed on an electronic traffic message board as an ambulance travels northbound on Chicagos Dan Ryan Expressway, Thursday, March 19, 2020.

Deaths climb to 4 in Illinois, Pritzker says grocery stores, interstates will never shut down

SPRINGFIELD As Gov. JB Pritzker announced three more COVID-19-related deaths and 134 new confirmed cases Thursday, he also expressly asserted that interstate highways, gas stations, grocery stores and other essential services will not close as a response to the pandemic.

I want to address some of the rumors that have been running around, Pritzker said. Essential services will not close. Interstates, highways and bridges will stay open. Grocery stores, pharmacies, gas stations these sources of fundamental supplies will continue to operate.

There is no need to run out and hoard food, gas or medicine, he said. Buy what you need, within reason. There is enough to go around as long as people do not hoard. We will never shut these services down.

The governor made that statement at his daily COVID-19 briefing in Chicago, where he also announced the three deaths, a Will County resident in his 50s, a Cook County resident in her 80s and an out-of-state resident in her 70s who was in Sangamon County bringing the states confirmed death count to four.

He also announced temporary tax relief for some bar and restaurant owners and cautioned that a shutdown of schools could last longer than a March 31 scheduled reopen date.

I also think that parents should be contemplating the possibility that that might be extended, he said of the scheduled March 31 return date.

Pritzker also said the state is evaluating every day as to whether a shelter-in-place order might be necessary, as, he said, experts are advising, this is going to take longer than people have expected.

Pritzker said the effort is largely aimed at staying ahead of countries like Italy, where there are more than 40,000 confirmed cases and more than 3,400 deaths. Social distancing, or staying home, remains the most important preventative measure.

So when I make decisions about this, this is about how do we operate faster and better than Italy and other countries that have seen this grow exponentially for a very long period of time, he said, noting that lack of testing means an increased reliance on mathematicians extrapolating available data over the entire population.

And Im gonna continue to listen to the experts to do the right thing, that the triggers are really in what the experts are seeing, he said.

Chicago Mayor Lori Lightfoot ordered Thursday that any city resident confirmed as having or showing symptoms of COVID-19 must stay home or risk a citation. The suburban village of Oak Park issued a shelter-in-place order which starts Friday, but it allowed for several exemptions, including obtaining essential services such as grocery shopping or medical care.

Pritzker also said the number of confirmed cases now at 422 will continue to grow as testing ramps up. According to the Illinois Department of Public Healths new website, coronavirus.illinois.gov, a total of 3,151 people had been tested in the state as of Thursday.

The states capacity for testing has increased from about 200 people per day to more than 1,000 on Wednesday, Pritzker said, adding it will be two-plus thousand in the next few days.

But, he said, the expected increase in coronavirus cases is also due to the virus spread, not just the increase in testing. He said the virus can also be spread by people who have it but have not been tested or have not shown symptoms.

So we know this is growing substantially. And until there are more and more tests, we will be in this situation of just seeing the numbers rise because the testing is rising, Pritzker said. We hope that there will be a cresting. In some countries in Asia, theres been a cresting because theyve implemented some of the measures that we have implemented here. Weve done it earlier here, but that doesnt mean that were not going to see a lot of cases of COVID-19, and frankly more deaths.

Dr. Ngozi Ezike, IDPH director, said expansion of private testing labs will allow the agency to continue to target its testing at the most vulnerable populations, such as nursing home patients and the staff that care for them.

Pritzker said he called up members of the National Guard to help set up drive-thru testing sites among other logistical and transportation efforts.

The Guard is also doing critical work planning for the weeks and months ahead, including expanding our health care capacity by potentially refitting and reopening previously closed hospitals, he said.

In terms of concrete action in response to the virus Thursday, Pritzker signed another executive order relaxing insurance rules for telemedicine, which allows patients to see a doctor remotely, such as through a video call.

For Medicaid plans and those regulated by the Illinois Department of Insurance, the executive order calls for providers to be reimbursed at the same rate at which they are reimbursed for in-person visits, among other regulatory changes.

This order will allow more providers to get reimbursed for these services and allow patients more flexibility and safety in getting the medical guidance and care that they need, he said.

Pritzker said his staff also worked with grocery stores and retail industry advocates to implement senior shopping hours.

In economic action, Pritzker said he directed the Department of Revenue to defer sales tax payments for small- and medium-sized bars and restaurants that paid less than $75,000 in sales tax last year. Those businesses will not be charged late payment penalties or interest on payments due in March, April or May.

He also announced that the U.S. Small Business Administration has approved the states eligibility in all 102 counties for disaster assistance loans up to $2 million for small businesses facing financial hardship.

Read the original:
Deaths climb to 4 in Illinois, Pritzker says grocery stores, interstates will never shut down - Alton Telegraph

1. Firearm use and related crime rates, deaths and injuries have increased disproportionately in the United States compared to other high-income countries over the last decade.

2. Firearm related violence is associated with significant financial, psychosocial and physical harm to communities.

3. Individual and community-level preventative efforts around firearm-related violence and a greater awareness of related implications of firearm use are warranted in the United States and globally.

Study Rundown: Firearm usage, crime rates, related deaths and injuries have significantly increased in the United States over the last decade. Compared to other high income countries, firearm-related death rates were over 11-fold higher in the United States compared to 28 other high-income countries in 2015, with disproportionately higher rates of firearm deaths, firearm homicides, public mass shootings, and both civilian and police deaths in encounters. Firearm suicide rates were higher in rural settings, among men and older adults, and among White communities compared to Black communities. In comparison, firearm homicide victimization rate were higher in urban settings, among Black communities compared to White communities, among men, and ages 20 to 24 years.

While data on firearm related fatalities is generally reliable, data on non-fatal shootings through the Centers for Disease Control is less reliable in the United States. Similarly, crime-related gun use estimates are likely underestimated.

Apart from death and injuries, firearms and exposure to violence also contribute towards other problems and related costs. These include an increased risk of psychiatric (e.g. post-traumatic stress disorder, depression, anxiety and others), emotional (e.g. withdrawal, anger, nervousness and despair), behavioral (e.g. substance abuse, violence, poor academic performance, promiscuous behavior) and health complications (e.g. asthma, heart disease and others). Community-level costs related to firearm injuries and deaths through Medicaid, insurance premiums and uncompensated debt, as well as those related to criminal law enforcement and downstream consequences of high crime communities may be considered. National medical costs of initial hospitalizations for firearm injury have been estimated close to $750 million per year, and do not account for significant hospital-related expenditures and high re-admission rates with related complications.

This review identifies the United States as an outlier in terms of firearm related morbidity and mortality, and related financial, psychosocial and health related sequelae for victims, perpetrators and communities. The findings call for individual and community-level preventative efforts around firearm related violence and a greater awareness of their related implications in the United States and globally.

Click to read the study in Current Trauma Reports

Relevant reading: Global Mortality From Firearms: 1960-2016

Image: PD

20202 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from2 Minute Medicine, Inc. Inquire about licensinghere. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Read more from the original source:
Morbidity and mortality associated with gun violence in the United States - 2 Minute Medicine

SAN FRANCISCO, March 20, 2020 /PRNewswire/ --MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled new research conducted among registered members of myRAteam, the social network for people living with rheumatoid arthritis (RA). Key findings spanned topics including patient satisfaction with their doctors, the impact RA has on quality of life, and common symptoms and flare-up triggers.

"Joint pain is just the tip of the iceberg for those living with rheumatoid arthritis. You've got to treat the whole person, not just their obvious symptoms," said Eric Peacock, cofounder and CEO of MyHealthTeams. "RA patients in this research made it clear that the best rheumatologists are those who take the time to truly understand the full range of symptoms and the quality of life impact people with RA are experiencing. The gap between patients satisfied and dissatisfied with their doctors was stark."

Patient Satisfaction: Determined by listening/understanding, time spent, and breadth of discussionThere is a high correlation between treatment satisfaction and doctor satisfaction, so if treatment isn't working to control a patient's RA, it's unlikely she will be satisfied with her doctor. But treatment effectiveness isn't the only driver. The study revealed a significant experience gap between those who are satisfied or not with their doctors. Among the 57% of RA patients who report overall satisfaction with their doctors: 87% feel their doctor listens to them and understands their needs; 81% believe their doctor spends enough time with them; 74% report their doctor addresses symptoms such as pain, depression and anxiety; 65% discuss treatment side effects with their doctor; and 52% say their doctor has worked with them to develop a long-term plan. Among the 43% of RA patients who report overall dissatisfaction with their doctors, these numbers drop to 24%, 26%, 20%, 29% and 12% respectively.

Impact on Quality of Life: Daily challenges and emotional impacts take toll at home, work and beyond RA, a chronic inflammatory condition in which the body's immune system attacks its own tissue, including joints, has wide-ranging impact on quality of life.

Further, the emotional toll of RA is significant.

Symptoms and Triggers: Aggravated by environmental factors, disease causes symptoms well beyond joint pain and stiffnessBeyond the joint pain and stiffness experienced by nearly everyone surveyed, myRAteam members report a broad spectrum of symptoms, including:

The top reported triggers for flare-ups of RA symptoms are stress (79%) and cold weather (73%).

This research was conducted among registered members of myRAteam. 374 individuals responded to the online survey. Full survey findings are available at https://www.myrateam.com/resources/the-results-are-in-people-living-with-rheumatoid-arthritis-are-more-satisfied-with-their-doctors-when-they-feel-heard-and-understood

About MyHealthTeamsMyHealthTeamsbelieves that if you are diagnosed with a chronic condition, it should be easy to find and connect with others like you. MyHealthTeams creates social networks for people living with a chronic health condition. Millions of people have joined one of the company's 35 highly engaged communities focusing on the following conditions: Crohn's and colitis, multiple sclerosis, lupus, fibromyalgia, pulmonary hypertension, spondylitis, eczema, myeloma, hyperhidrosis, vitiligo, rheumatoid arthritis, psoriasis, leukemia, lymphoma, irritable bowel syndrome, Parkinson's, Alzheimer's, epilepsy, hemophilia, hidradenitis suppurative, depression, heart disease, type 2 diabetes, osteoporosis, COPD, chronic pain, migraines, food allergies, obesity, HIV, PCOS, endometriosis, breast cancer and autism. MyHealthTeams' social networks are available in 13 countries.

Read this article:
New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors - Monterey County Weekly

INTRODUCTION:

The objective of this study was to assess efficacy and safety of repository corticotropin injection (RCI) in subjects with activerheumatoid arthritis(RA) despite treatment with a corticosteroid and one or two disease-modifying antirheumatic drugs (DMARDs).

All subjects received open-label RCI (80 U) twice weekly for 12weeks (part 1); only those with low disease activity [LDA; i.e., Disease Activity Score 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)<3.2] were randomly assigned to receive either RCI (80 U) or placebo twice weekly during the 12-week double-blind period (part 2). The primary efficacy endpoint was the proportion of subjects who achieved LDA at week 12. Secondary efficacy endpoints included proportions of subjects who maintained LDA during weeks 12 through 24 and achieved Clinical Disease Activity Index (CDAI)10 at weeks 12 and 24. Safety was assessed via adverse event reports.

Of the 259 enrolled subjects, 235 completed part 1; 154 subjects (n=77 each for RCI and placebo) entered part 2, and 127 (RCI, n=71; placebo, n=56) completed. At week 12, 163 subjects (62.9%) achieved LDA and 169 (65.3%) achieved CDAI10 (both p<0.0001). At week 24, 47 (61.0%) RCI-treated and 32 (42.1%) placebo-treated subjects maintained LDA (p=0.019); 66 (85.7%) RCI-treated and 50 (65.8%) placebo-treated subjects maintained CDAI10 (p=0.004). No unexpected safety signals were observed.

RCI was effective and generally safe in patients with active RA despite corticosteroid/DMARD therapy. By week 12,>60% of patients achieved LDA, which was maintained with 12 additional weeks of treatment. Most patients who achieved LDA maintained it for 3months after RCI discontinuation.

Clinicaltrials.gov identifierNCT02919761.

See more here:
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial - DocWire...

OBJECTIVE:

This study aimed to longitudinally evaluate the association betweenrheumatoid arthritis(RA) and locomotive syndrome (LS) in RA patients using the 25-question Geriatric Locomotive Function Scale (GLFS-25).

Subjects were 58 RA patients (female, 48 (82.8%); mean age, 60.910.9 years) who had GLFS-25 scores available for five consecutive years and who did not have LS at baseline (i.e., GLFS-25<16 points). Associations between DAS28-CRP and the development of LS were determined using linear regression analysis and receiver operating characteristic (ROC) curve analysis.

Subjects were divided into the LS group (n=15, GLFS-2516 points) and Non-LS group (n=43, GLFS-25<16 points) based on GLFS-25 scores at the 5th year of the study period. In the LS group, DAS28-CRP worsened every year. The linear regression model adjusted for age and sex revealed that GLFS-25 increased by 3.80 (95% confidence interval: 1.81-5.79) each time DAS28-CRP increased by 1 (p<0.001). Among patients in remission (DAS28-CRP <2.3), 13.5% had LS. ROC curve analysis yielded a five-year mean DAS28-CRP of 1.99 (sensitivity, 86.7%; specificity, 62.8%) as the cut-off point for the development of LS.

Tight control of RA disease activity for deeper remission may be needed to prevent the development of LS.

Read the rest here:
Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study - DocWire...

OBJECTIVE:

The aim of this study was to evaluate the discriminant capability of the Patient Acceptable Symptom State (PASS) according to disease activity, remission/low disease activity indices and quality of life indices in patients withpsoriatic arthritis(PsA).

Consecutive patients with PsA were enrolled in this cross-sectional study. At each visit, the patients underwent a complete physical examination and their clinical/laboratory data were collected. Disease activity was assessed using the Disease Activity Score forPsoriatic Arthritis(DAPSA) and remission/low disease activity using the DAPSA minimal disease activity (MDA) and very low disease activity (VLDA) criteria. ThePsoriatic ArthritisImpact of Disease (PsAID) and the Health Assessment Questionnaire-Disability Index scores were also collected. Finally, PASS was assessed by asking all patients to answer yes or no to a single question.

Patients who answered yes to PASS showed a significantly better overall mean DAPSA score than those who were not in PASS. Furthermore, patients in PASS showed a significantly lower level of systemic inflammation, lower Leeds Enthesitis Index score, a significantly lower impact of disease (PsAID), lower pain and better function than patients who answered no to PASS. A moderate to good agreement was found between PASS, MDA, DAPSA low disease activity and PsAID score 4. Good sensitivity and specificity were found with PASS with respect to DAPSA low disease activity, and although PASS is sensitive in the identification of patients with MDA, DAPSA remission and VLDA it lacks of specificity.

This study showed that PASS might be used as an alternative to determine disease activity in patients with PsA in real clinical practice, mainly in patients with low disease activity according to DAPSA criteria.

Read this article:
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -...

Home Topics Pain Management

The FDA has approved Advil Dual Action with Acetaminophen (GlaxoSmithKline), the first over-the-counter (OTC) fixed-dose combination therapy containing ibuprofen and acetaminophen for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis.

Each caplet contains 125mg of Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) and 250mg of acetaminophen and is indicated for adults and children 12 years of age and older. The approval was based on study data that showed use of the fixed-dose combination therapy was associated with superior pain relief compared with the individual components taken alone.

Advil Dual Action with Acetaminophen is expected to be available nationwide sometime during 2020.

GlaxoSmithKline recently received FDA approval for another OTC pain reliever, Voltaren Arthritis Pain (diclofenac topical gel), for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults 18 years old. The OTC formulation is the same as the prescription strength (10mg of diclofenac sodium per gram or 1%). It is expected to be available in spring 2020.

For more information visit gsk.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Pain ManagementClose

Go here to see the original:
FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain - Rheumatology Advisor

The Rheumatoid Arthritis Treatment Market study offers an in-depth analysis of the current market trends influencing this business vertical. The study also includes market valuation, market size, revenue forecasts, geographical spectrum and SWOT Analysis of the industry. In addition, the report depicts key challenges and growth opportunities faced by the industry bigwigs, in consort with their product offerings and business strategies.

A collective analysis of Rheumatoid Arthritis Treatment Market offering an exhaustive study based on current trends influencing this vertical across various geographies has been provided in the report. Also, this research study estimates this space to accrue considerable income during the projected period, with the help of a plethora of driving forces that will boost the industry trends during the forecast duration. Snippets of these influences, in tandem with countless other dynamics relating to the Rheumatoid Arthritis Treatment Market, like the risks that are predominant across this industry along with the growth prospects existing in Rheumatoid Arthritis Treatment Market, have also been charted out in the report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2263

The report covers exhaustive analysis on:

Regional analysis includes

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2263

The report provides extensive data concerning the market share that each one of these companies presently gather throughout this business, followed by the market share that they are anticipated to acquire by the end of the predicted timeframe. Also, the report expounds on details relating to the goods manufactured by these firms, that would help new industry participants and major stakeholders work on their competition and portfolio strategies. In addition, their policymaking process is likely to get easier since the Rheumatoid Arthritis Treatment Market report also enumerates an idea of the trends in product prices and the revenue margins of all the major companies partaking in the industry share.

Queries that the Rheumatoid Arthritis Treatment Market report answers in respect of the regional landscape of the business domain:

Get Full Report Access athttps://www.xploremr.com/cart/2263/SL

Significant takeaways from the study:

The Rheumatoid Arthritis Treatment Market report hosts excess deliverables that may be highly advantageous. Say for instance, the report emphasizes information regarding market competition trends extremely essential data subject to contender intelligence and the current industry drifts that would enable shareholders to compete and take advantage of the biggest growth opportunities in the Rheumatoid Arthritis Treatment Market.

Another vital takeaway from the report can be accredited to the industry concentration rate that could help stakeholders to speculate on the existing sales dominance and the probable trends of the forthcoming years.

Additional deliverables mentioned in the report include details pertaining to the sales channels deployed by prominent sellers in order to retail their status in the industry, including direct and indirect marketing.

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original:
Rheumatoid Arthritis Treatment Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2029 - Daily...

Rheumatoid Arthritis Diagnosis Tests Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2017 2025 as the forecast period to estimate the market size for Rheumatoid Arthritis Diagnosis Tests.

This industry study presents the Rheumatoid Arthritis Diagnosis Tests Market size, historical breakdown data 2014-2019 and forecast 2017 2025. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Rheumatoid Arthritis Diagnosis Tests Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

Rheumatoid Arthritis Diagnosis Tests Market report coverage:

The Rheumatoid Arthritis Diagnosis Tests Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Rheumatoid Arthritis Diagnosis Tests Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Rheumatoid Arthritis Diagnosis TestsMarket Report:

In this study, the years considered to estimate the market size of Rheumatoid Arthritis Diagnosis TestsMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2017 2025

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rheumatoid Arthritis Diagnosis Tests Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original here:
Rheumatoid Arthritis Diagnosis Tests Market expected to Witness a Sustainable Growth over 2017 2025 - Feed Road

Tart cherry juice is the latest health rage and for good reason. The cancer-fighting beverage may also protect against heart disease, reduce arthritis symptoms, and help you sleep more soundly.

"Tart cherries are loaded with important nutrients, but you'd have to eat an entire bag of them to obtain all the benefits you get by sipping the juice," says Michele Turcotte, M.S., R.D., a dietitian and nutritionist in Lake Geneva, Wisconsin. "Its juice contains many antioxidants and anti-inflammatory agents, which can help alleviate a variety of ailments like asthma symptoms and pain."

Turcotte explains that tart cherries, like all red fruits and vegetables, are rich in anthocyanins, a particularly potent antioxidant phytochemical.

"Anthocyanins encourage healthy circulation, ensure proper nerve function, and offer cancer-fighting properties," says the expert. A research study published in the Journal of Nutrition says that tart cherry juice provides older adults great protection against the development of heart disease, cancer and age-related cognitive decline.

Here are more health benefits:

* Heart disease and diabetes. The quercetin found in tart cherry juice is another powerful antioxidant that helps prevent free radical damage caused by low-density lipoprotein or LDL, according to a 2013 study. When LDL cholesterol is oxidized, its more likely to stick to arterial walls, forming plaque that contributes to heart attack and stroke.

Another study published in the International Journal of Preventative Medicine noted that intake of high levels of quercetin were associated with reduced risk of type 2 diabetes.

* Insomnia. Drinking an 8-ounce glass of tart cherry juice in the morning and the evening may be a better and safer way to treat insomnia than taking drugs, according to researchers at Louisiana State University. Tart cherries are a natural source of melatonin, a hormone that helps regulate the sleep-wake cycle.

* Sports recovery and muscle damage. Marathon runners who consumed 8 ounces of tart cherry juice twice daily for five days prior to a marathon, on the day of the marathon, and then for two days afterward reported less muscle damage, soreness, inflammation, and protein breakdown than runners who consumed a placebo, according to research published in the Scandinavian Journal of Medicine and Science in Sports.

* Arthritis and gout. Tart cherry juice may reduce arthritis symptoms such as joint pain and inflammation, according to several studies. A 2012 study revealed that folks with osteoarthritis who drank tart cherry juice for 21 days had reduced symptoms of pain.

* Brain health. Since degenerative brain disorders like Parkinson's and Alzheimer's are thought to be causeed, in part, by oxidative stress, drinking tart cherry juice may have protective effects on brain cells. In fact, in one study, older adults with mild-to-moderate cognitive decline consumed 6 ounces of tart cherry juice daily or a placebo for 12 weeks. The adults in the tart cherry juice group experienced improvement in verbal fluency, short term memory, and long-term memory, whereas the placebo group experienced no improvement.

2020 NewsmaxHealth. All rights reserved.

Read the rest here:
Fight Inflammation With Tart Cherry Juice - Newsmax

SCCA psychiatrist Dr. Nicole Bates, who splits her time between patients with cancer and those without, said uncertainty can either demoralize or empower people. Some cancer patients, she said, become depressed or anxious, while others develop incredible resilience.

So many of us are grappling with the initial affront and lack of control, she said, regarding the current crisis. Ive been struck by how my patients find strength through uncertainty, how they use it to crystallize priorities for living each day.

Fred Hutch psychologist and patient outcomes researcher Dr. Salene Jones described resilience as the ability to adapt to stressful events.

A person can be sad, unhappy or stressed, and still, ultimately, be resilient, she said, pointing to resiliency tips recently published by the American Psychological Association. Resilience is not the absence of feeling stressed but finding a way to cope with it. Its OK to be a mess sometimes. Just not all the time.

Cancer patients have also been staying connected, while apart, for years.

#BCSM (short for breast cancer social media) holds weekly Twitter chats, drawing patients and survivors from around the world. Ditto for other patient communities on Twitter, including for brain cancer, lung cancer, pancreatic cancer and many more. People living with disease also regularly gather in closed Facebook groups or vast online patient communities like Inspire, Smart Patients, Colontown and others to ask for advice, grouse about side effects and gain strength from others.

Its easy to become isolated and lonely, said Renee Kaiman, a 38-year-old metastatic breast cancer patient and mother of two from Toronto, Canada. Right now, its good to reach out to people via FaceTime or have phone calls. Try to do things you enjoy to keep your mood up.

Staying connected with yourself is also key, especially when dealing with isolation and angst.

This is a great time to explore creative projects, to listen to music, to try new recipes theyve never tried before, Kleinhofer said. We cant control whats happening right now, but we can control how we respond to it. Things may seem crazy but every day theres something to be thankful for. Find what makes you happy and focus on that, whether its family or friends or the sound of birds chirping outside. And if you start to spin out of control, thats when yoga, meditation and mindfulness can come into play.

More here:
Lessons from cancer patients in the time of coronavirus - Fred Hutch News Service

In this new business intelligence Stem Cell-Derived Cells market report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Stem Cell-Derived Cells market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Stem Cell-Derived Cells market.

With having published myriads of Stem Cell-Derived Cells market reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

The Stem Cell-Derived Cells market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the Stem Cell-Derived Cells market players could create collaborations in a bid to sustain production footprint.

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28780

What does the Stem Cell-Derived Cells market report contain?

Readers can get the answers of the following questions while going through the Stem Cell-Derived Cells market report:

And many more

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Read the original post:
Stem Cell-Derived Cells Value Projected to Expand by 2019-2025 - 3rd Watch News

Equities research analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce ($0.61) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Magenta Therapeutics earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.57). Magenta Therapeutics reported earnings of ($0.44) per share in the same quarter last year, which suggests a negative year over year growth rate of 38.6%. The business is expected to report its next earnings results on Thursday, May 14th.

On average, analysts expect that Magenta Therapeutics will report full-year earnings of ($2.17) per share for the current year, with EPS estimates ranging from ($2.25) to ($2.13). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.90) per share, with EPS estimates ranging from ($2.13) to ($1.58). Zacks Investment Researchs EPS calculations are an average based on a survey of research analysts that follow Magenta Therapeutics.

Magenta Therapeutics (NASDAQ:MGTA) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.59) EPS for the quarter, missing the Zacks consensus estimate of ($0.58) by ($0.01).

In other news, insider John C. Davis, Jr. sold 11,294 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $15.04, for a total value of $169,861.76. Following the completion of the transaction, the insider now owns 19,598 shares of the companys stock, valued at $294,753.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jason Gardner sold 11,200 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $15.25, for a total value of $170,800.00. Following the completion of the transaction, the insider now directly owns 251,212 shares of the companys stock, valued at approximately $3,830,983. The disclosure for this sale can be found here. In the last three months, insiders sold 25,391 shares of company stock valued at $384,406. Company insiders own 10.90% of the companys stock.

Several large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in Magenta Therapeutics by 57.3% during the fourth quarter. Bank of Montreal Can now owns 2,652 shares of the companys stock valued at $40,000 after buying an additional 966 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Magenta Therapeutics by 5.0% during the fourth quarter. Bank of New York Mellon Corp now owns 62,868 shares of the companys stock valued at $953,000 after buying an additional 2,985 shares in the last quarter. Citigroup Inc. boosted its stake in Magenta Therapeutics by 248.7% during the fourth quarter. Citigroup Inc. now owns 6,876 shares of the companys stock valued at $104,000 after buying an additional 4,904 shares in the last quarter. Metropolitan Life Insurance Co NY bought a new position in Magenta Therapeutics during the third quarter valued at about $76,000. Finally, Ikarian Capital LLC bought a new position in Magenta Therapeutics during the fourth quarter valued at about $131,000. 65.41% of the stock is owned by institutional investors.

Shares of MGTA opened at $6.70 on Friday. The company has a market cap of $391.31 million, a P/E ratio of -3.27 and a beta of 2.77. The stock has a fifty day moving average price of $11.43 and a 200 day moving average price of $11.87. Magenta Therapeutics has a 12 month low of $6.18 and a 12 month high of $21.00.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

Recommended Story: What is quantitative easing?

Get a free copy of the Zacks research report on Magenta Therapeutics (MGTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
Magenta Therapeutics Inc (NASDAQ:MGTA) Expected to Post Earnings of -$0.61 Per Share - Redmond Register

With rare diseases, 72 percent out of the 7000 known are genetic, and 70 percent of those start in childhood. The lack of scientific knowledge and the quality of information often delay diagnosis or lead to misdiagnosed cases, losing precious time that can be vital to find treatment before it's too late.This situation is changing with the advent of genetic medicine. an example is Emedgene's artificial intelligence software, which is the worlds first completely automated genetic interpretation platform using machine learning algorithms.Digital Journal spoke with Einat Metzer, CEO and Co-Founder of Emedgene to talk about the new genetic interpretation software.Digital Journal: How are rare diseases classified?Einat Metzer: Rare diseases defined by the number of people affected. In the U.S., any disease that affects fewer than 200,000 people is defined as rare, in Europe, its any disease affecting fewer than 1 in 2000 people.There are around 6000 known rare diseases, and that number is growing. Whats interesting to know, is that although they are each individually rare, collectively they impact over 300 million people. Those patients have a very difficult time receiving a diagnosis for their disease, and typically go through a diagnostic odyssey lasting on average 5-7 years. Its also worth noting that most rare diseases have a genetic basis, and appear in early childhood. DJ: Is sufficient funding and research invested into rare diseases? What are the factors that influence this?Metzer: There are two challenging aspects to rare diseases, the first is the identification of a rare disease, because obviously, physicians arent familiar with every disease affecting only tens or hundreds of patients worldwide. The second difficult aspect is developing treatments for diseases impacting small numbers of patients. The good news is countries and healthcare systems are increasingly recognizing the need to cover genetic testing for the identification of rare diseases. As of today, over 50% of the US population has insurance coverage for next generation sequencing. However, even insurance coverage for the tests does not entirely solve the problem. Sequencing a patients DNA is easily done, but understanding what variants in a patients genome mean is still quite challenging. Every patient has millions of harmless genetic variants, and only one disease-causing mutation. As a result, geneticists can spend hours manually reviewing hundreds of variants and looking for evidence for the disease in databases and the literature. There are fewer than 5,000 geneticists worldwide available to interpret patients genetic data, resulting in an interpretation bottleneck. Even as more patients become eligible for genetic testing, the workforce capable of diagnosing them is not growing fast enough. We estimate the worldwide capacity of interpretation is capped at roughly 2.4 million tests, less than the predicted rare disease testing volume for 2020. DJ: How can machine learning help?Metzer:Machine learning technologies can reduce the manual labor of interpretation, by offloading both the research and deep analysis tasks from geneticists. Machine learning is a buzzword, widely used, and applied to many types of solutions. Were talking about a unique application of the technology here, where we wont use a single algorithm to solve a single problem. Instead, we need to apply a set of algorithms designed to automate different aspects of the geneticists workflow. On the one hand, the geneticists work is to review thousands of data points for every patients test, and use them to come to a conclusion on the single genetic variant thats causing the disease. We can certainly apply machine learning algorithms to review those data points. But we can go a step further, and collect the data points most likely to impact their decision, and include those in our recommendations. The second labor-intensive task geneticists perform, is looking for the most up-to-date information in databases and the published literature. Thats a task well suited for Natural Language Processing, which can be used to augment existing databases with information curated from the literature. DJ: How does Emedgenes AI software work?Metzer:Emedgenes AI-powered genomic analysis platform tries to do just that, automate the labor-intensive parts of the geneticists workflow, so interpreting a patients genetic test takes less time and effort, and accuracy is not compromised. The goal is to scale the genetic testing interpretation in healthcare systems, so they can offer personalized care to a broader population. Our AI consists of dozens of different algorithms, each solving a different problem, all coming together to automate the genetic testing interpretation workflow. The platform is able to automatically identify the disease-causing variant, compile the evidence, and present it to the geneticist on the case for review. The machine learning algorithms utilize a proprietary knowledge graph that continuously incorporates new knowledge. The knowledge graph contains over 85,000 entities and 340,000 connections today, including unique information curated from the literature that has not yet made its way into public databases.DJ: What were the main challenges when developing the software?Access to large high-quality data sets is a major challenge in developing AI solutions in healthcare in general. For our supervised learning algorithms - those that require labeled data for training the algorithm - once we obtained the data, labeling was a challenge as well. The level of education required to annotate healthcare datasets is quite high.Fortunately, there are good solutions to both problems, both from the scientific and AI perspective. DJ: Are there any case studies you can share, to show the benefits of the approach?Metzer:Weve studied the accuracy of our interpretation algorithms with Baylor Genetics. In the 180-case study, our AI successfully identified the disease-causing mutation in 96% of the cases. Another of our customers, Greenwood Genetic Center, was able to reduce time spent per case by 75%, which was translated directly into shorter turn around times for patients waiting for a genetic diagnosis.

Continued here:
Q&A:Transforming genetic medicine as the medical standard of care (Includes interview) - Digital Journal

Dr. Segun Fatumo is a computer scientist with specialization in bioinformatics with keen interest in the genetic impact of non-communicable diseases in Africa and bioinformatics capacity building in Africa. He has been involved in various genetic projects including analysing a large-scale genomic dataset from Ugandan population. During his PhD, he was able to identified twenty-two (22) potential novel drug targets against malaria. Currently, he is an Assistant Professor at the London School of Hygiene and Tropical Medicine (University of London). Genetic Literacy Project (GLP) interviewed him to shed more light on the importance, challenges and future direction of a recent genetic research that he was a leading

As one of the lead authors of your recently published paper, what motivated this research project?

Precision medicine is fundamentally going to change healthcare. Genomic medicines is a key component of precision medicine with enormous potential to inform clinical medicine. One potential limitation to genomic medicine is the underrepresentation of African and other populations in genomics research. Previous studies have warned that a much broader range of populations should be investigated to avoid genomic medicine being of benefit merely to a privileged few. This is especially problematic, as previous studies have shown that Africa studies contribute an outsized number of associations relative to studies of similar sizes in Europeans. To demonstrate the potential of African genomes as a great resource for genomic medicine, we collected and analyzed genome-wide data from 6,407 individuals from Uganda.

What is the value of collecting more genomic data from African populations which are badly underrepresented in genomic databases.

Our findings from even modest side studies highlight the importance and usefulness of examining genetically diverse populations within Africa. Findings from large-scale studies from Africa may foster the development of new treatments that will benefit people living in Africa as well as people of African descent around the world.

What sort of challenges did you face in the study, and how did you overcame them?

So many challenges including community engagement, ethics, recruitment, etc. Globally, genomics research and specifically recruitment of participants regardless of the continent is always challenging. However, 60% of Africans live in rural areas. Prospective participants are more likely to be poor and to have limited access to healthcare and education. This means that the carrying out of research in these settings invariably presents challenges of a different order to those in higher income countries. Researchers should not exploit these challenges.

Is the value of this research project beyond Uganda and why?

Yes. Findings from our study may foster the development of new treatments that will benefit people living in Africa as well as people of African descent around the world.

What were the responses that you have received so far about the findings?

Enormous responses. I find it difficult to attend to all media requests.

What is the future direction of the research?

While there is an urgent need to perform large-scale genomic research in Africa, several ongoing initiatives such as H3Africa and the Nigerian 100K Non-Communicable Diseases Genetic Heritage Study (NCD-GHS) could provide the data to improve the evidence base and make genome medicine useful to diverse populations.

How do you see the future of genetics and bioinformatics in Africa?

I think we are now on the right track. We have established the Nigerian Bioinformatics and Genomics Network (NBGN). There are also other initiatives. We are now focusing on building capacity in Africa.

Olumide Odeyemi is a research scientist with a doctoral degree from the University of Tasmania, Australia. His areas of expertise and interest include food microbiology, microbial food safety and quality, aquaculture microbiology and research communication. Follow him on Twitter @olumide_odeyemi

Dr. Segun Fatumo is an assistant professor of genetic epidemiology and bioinformatics at the London School of Hygiene & Tropical Medicine. Follow him on Twitter @SFatumo

View original post here:
Studying the African genome could yield new medical treatments for everyone - Genetic Literacy Project

Jane Pei-Chen Chang,1,* Kuo-Hao Huang,1,* Chieh-Hsin Lin,2,3 Hsien-Yuan Lane1,3,4

1Department of Psychiatry & Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan; 2Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan; 3Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; 4Department of Psychology, College of Medical and Health Sciences, Asia University, Taichung, Taiwan

*These authors contributed equally to this work

Correspondence: Chieh-Hsin LinDepartment of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Road, Niaosong District, Kaohsiung 833, TaiwanTel +886-7-7317123 ext. 8753Fax +886-7-7326817Email cyndi36@gmail.com

Hsien-Yuan LaneDepartment of Psychiatry, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, TaiwanTel +886-4-22062121 ext. 1074Fax +886-4-2236-1230Email hylane@gmail.com

Background: Visual learning plays an important role in general populations and patients with schizophrenia. Genetic influences on visual learning remain unknown. Two functional single nucleotide polymorphisms (SNPs), Ser704Cys of the DISC1 gene and M24 (rs1421292) of the G72 gene, are strongly associated with pathogenesis and pathophysiology of schizophrenia. This study examined these two SNPs effects on visual learning in schizophrenia patients.Methods: Two hundred seventy-one patients (mean age, 37.0 years [SD = 9.3]; 159 men) with chronic schizophrenia were genotyped for the DISC1 Ser704Cys and G72 M24 SNPs and assessed for visual learning with Visual Reproduction II (delayed reproduction) of Wechsler Memory Scale III (WMS-III). For comparison, verbal learning (using Wordlist II of WMS-III) and attention (by Continuous Performance Test) were also measured.Results: The DISC1 Ser carriers excelled DISC1 Cys/Cys homozygotes in visual learning (p=0.004, effect size: 0.43), but not in other cognitive functions. G72 M24 A-allele carriers and G72 M24 T/T homozygotes performed similarly (effect size: 0.07). In SNP-SNP interaction analysis, the patients with Ser carrier_T/T had better visual learning than those with Cys/Cys_T/T (p=0.004, effect size: 0.70) and those with Cys/Cys_A-allele carrier (p=0.003, effect size: 0.65). Education had a positive effect (p=0.007), while negative symptoms had a negative effect (p< 0.001) on visual learning.Conclusion: The findings suggest that genetic variations in DISC1 Ser704Cys and G72 M24 affect visual learning in schizophrenia patients. The effect sizes of SNP-SNP interaction surpassed the sum (0.50) of effect sizes from two individual genes, suggesting synergistic DISC1-G72 interaction.

Keywords: attention, DISC1, G72, visual and verbal learning, schizophrenia

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients | NDT - Dove Medical Press